Effect of intracoronary administration of AAV1/SERCA2a on ventricular remodelling in patients with advanced systolic heart failure : results from the AGENT-HF randomized phase 2 trial
Topic:
Gene and cell therapy
Speaker:
Professor J. Hulot (Paris, FR)
Event:
HEART FAILURE 2016
Congress Presentation
About the speaker
Professor Jean-Sebastien Hulot
Paris Cardiovascular Research Center (PARCC), Paris (France)
12
presentations
1
follower
22 more presentations in this session
Zofenopril combined with xanthine oxidase inhibitors may improve survival in post-myocardial infarction patients as compared to placebo or other ACE-inhibitors
Long-term effects and sustainability of collaborative disease management in systolic heart failure - the extended interdisciplinary network heart failure study
Speaker: Professor C. Angermann (Wuerzburg, DE)
An implantable pressure sensor for long-term wireless monitoring of cardiac function -first study in man
Speaker: Doctor J. Baranowski (Linkoping, SE)
Heart failure hospitalisation or cardiovascular death with empagliflozin in patients with type 2 diabetes and high cardiovascular risk: analysis over time in EMPA-REG OUTCOME
Speaker: Doctor D. Fitchett (Toronto, CA)
- …
Access the full session
Clinical Forum - Mon. 23 May 08:30 - Tues. 24 May 12:30
Speakers:
Professor J. Hulot, Professor C. Angermann, Doctor J. Baranowski, Doctor D. Fitchett, Professor S. Anker
About the event
ESC 365 is supported by
